BioCentury | Jan 22, 2020
Company News

Jan. 21 Company Quick Takes: First BCMA-targeted therapy gets Priority Review from FDA; plus Roche-Seattle Genetics, AZ-Merck, Chi-Med

...for hematopoietic stem cell transplant. The antibody-drug conjugate is indicated for use in combination with Bendeka...
BioCentury | Mar 1, 2019
Clinical News

FDA concludes Treanda will benefit from Bendeka's exclusivity protection

...FDA concluded that the scope of Orphan Drug exclusivity for cancer drug Bendeka bendamustine from Eagle...
...sponsor shows clinical superiority to Bendeka. The decision bars approval of any ANDA referencing either Bendeka...
...minutes for an infusion and more sodium chloride than Bendeka. Teva has U.S. rights to Bendeka...
BioCentury | Nov 10, 2016
Company News

Bendeka sales and marketing update

...Teva and Eagle said CMS issued a J-code, effective Jan. 1, for Bendeka bendamustine. The drug...
...that has progressed during or within six months of treatment with rituximab or rituximab-containing regiment. Bendeka...
...Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Eagle Pharmaceuticals Inc. (NASDAQ:ERGX), Woodcliff Lake, N.J. Business: Cancer Shannon Lehnbeuter Bendeka Centers...
BioCentury | Jun 11, 2016
Company News

Eagle soars after bendamustine patent ruling

...Eagle Pharmaceuticals Inc. (NASDAQ:EGRX), which last year granted Teva rights to bendamustine formulation Bendeka ( EP-3102...
...expires in 2026. The suit was a consolidated infringement case involving the patent. Treanda and Bendeka...
...approved to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin's lymphoma. FDA approved Bendeka...
BioCentury | Feb 15, 2016
Company News

Eagle Pharmaceuticals, Teva sales and marketing update

...Teva launched Bendeka bendamustine in the U.S. to treat chronic lymphocytic leukemia (CLL) and indolent B...
...Bendeka. The starting dose is 100 mg/m 2 for CLL and 120 mg/m 2 for NHL.Bendeka...
...or a mixture of sodium chloride and dextrose. Teva has exclusive, U.S. commercialization rights to Bendeka...
BioCentury | Jan 4, 2016
Finance

Big band swing

...options are inadequate Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) / Teva Pharmaceutical Industries Inc. (NYSE:TEVA) FDA approves Bendeka...
BioCentury | Dec 21, 2015
Clinical News

Bendeka bendamustine regulatory update

...FDA approved an NDA from Eagle for Bendeka bendamustine to treat chronic lymphocytic leukemia (CLL) and...
...has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen. Bendeka...
...see BioCentury, Feb. 23). Eagle Pharmaceuticals Inc. (NASDAQ:EGRX), Woodcliff Lake, N.J. Product: Bendeka bendamustine ( EP-3102...
BioCentury | Dec 21, 2015
Company News

Eagle Pharmaceuticals, Teva deal

...milestone payment from Teva under a 2015 deal granting Teva exclusive, U.S. rights to commercialize Bendeka...
...lymphoma (NHL). The milestone was triggered by FDA approval of the drug in the indications. Bendeka...
BioCentury | Dec 9, 2015
Company News

FDA approves Bendeka for CLL, NHL

...FDA approved Bendeka bendamustine RTD ( EP-3102 ) from Teva Pharmaceutical Industries Inc. (NYSE:TEVA) and Eagle...
...treatment with rituximab . Eagle CEO Scott Tarriff told BioCentury that Teva plans to use Bendeka...
...reconstituted into a 500 mL bag and requires 30-60 minutes for an infusion. He said Bendeka...
BioCentury | Oct 5, 2015
Finance

Event planner

...PDUFA date 10/12/15 Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) / Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Bendamustine RTD (EP-3102...
Items per page:
1 - 10 of 17